Compare Gilead Sciences, Inc. (GILD) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs J M Smucker Co — how do they compare? Gilead Sciences, Inc. trades at $136.45 (market cap $163.51B), while J M Smucker Co trades at $109.02 (market cap $11.65B). The key difference: Gilead Sciences, Inc. is far larger — about 14× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (4.04%). Which is the better fit depends on your goals.
| GILD | SJM | |
|---|---|---|
Market Cap | $163.51B | $11.65B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $117.05 |
52-Week Low | $108.22 | $89.53 |
Enterprise Value | $178.05B | $18.68B |
Dividend Yield | 2.49% | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
J.M. Smucker (SJM) trades at $113.00, up 3.85% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $1.23 billion for 2025, with negative profit margins, though revenue grew to $8.73 billion. Analyst consensus is a Buy with a $123.18 price target, supported by strong cash flow and a 4% dividend yield. Key growth drivers include Uncrustables and coffee brands, while fiscal 2027 sales are expected to decline 3-4%.
SJM presents a mixed outlook: valuation appears reasonable with a P/E of 22.05, but profitability concerns and high debt pose risks. Near-term catalysts include cost controls and brand innovation, yet competitive pressures and weak sales guidance may limit upside. The stock offers income via dividends, but investors should weigh execution risks against potential margin recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
